Pacific Biosciences (PACB) Q4 Earnings Surge 13.8% on Consumables and Clinical Adoption; SparkNex Launch Looms

Pacific Biosciences (NASDAQ:PACB) reported Q4 CY2025 results exceeding expectations, with sales rising 13.8% YoY to $44.65 million and a non-GAAP loss of $0.12 per share, 10.8% above consensus. Record consumables revenue and broader instrument placements for Revio and Vega platforms drove the quarter, supported by strong clinical adoption in rare disease and targeted genomics, with Europe seeing accelerated deployment. Management attributed higher gross margins to shifting clinical customers from pilot to full-scale use and positive early feedback on SparkNex, its next-gen chemistry, in beta. The 2026 outlook hinges on SparkNex’s commercial launch, which management expects to boost throughput and reduce per-genome costs, alongside deeper contract wins and disciplined cost management. CFO James Gibson cautioned against continued academic spending weakness. Key watchpoints include SparkNex’s adoption, growth in clinical and population-scale contracts, and margin expansion as the company transitions from short-reads.